149 related articles for article (PubMed ID: 11727277)
1. Intravenous glycoprotein IIb/IIIa inhibition in non-ST segment elevation acute coronary syndromes.
Chew DP; Roffi M; Topol EJ
Prog Cardiovasc Dis; 2001; 44(3):195-206. PubMed ID: 11727277
[TBL] [Abstract][Full Text] [Related]
2. The role of glycoprotein IIb/IIIa inhibition in the management of acute coronary syndromes.
Koller CF
Heart Lung; 2001; 30(5):321-9; quiz 330-1. PubMed ID: 11604974
[TBL] [Abstract][Full Text] [Related]
3. Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT.
Alexander JH; Harrington RA
Drugs; 1998 Dec; 56(6):965-76. PubMed ID: 9878986
[TBL] [Abstract][Full Text] [Related]
4. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
Adgey AA
Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518
[TBL] [Abstract][Full Text] [Related]
5. Optimizing glycoprotein IIb/IIIa receptor antagonist use for the non-ST-segment elevation acute coronary syndromes: risk stratification and therapeutic intervention.
Januzzi JL; Cannon CP; Theroux P; Boden WE
Am Heart J; 2003 Nov; 146(5):764-74. PubMed ID: 14597924
[TBL] [Abstract][Full Text] [Related]
6. [Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].
Auer J; Berent R; Lassnig E; Weber T; Maurer E; Eber B
Herz; 2003 Aug; 28(5):393-403. PubMed ID: 12928738
[TBL] [Abstract][Full Text] [Related]
7. [The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type].
Galli M; Maggioni AP; Vassanelli C; Tavazzi L
Ital Heart J Suppl; 2000 Feb; 1(2):202-11. PubMed ID: 10731377
[TBL] [Abstract][Full Text] [Related]
8. Platelet glycoprotein IIb/IIIa receptor antagonists in non-ST segment elevation acute coronary syndromes: a review and guide to patient selection.
Atwater BD; Roe MT; Mahaffey KW
Drugs; 2005; 65(3):313-24. PubMed ID: 15669877
[TBL] [Abstract][Full Text] [Related]
9. Management of acute ischaemic coronary syndromes beyond aspirin therapy: role of glycoprotein IIb/IIIa antagonists.
Gambhir DS
Indian Heart J; 1998; 50(2):151-4. PubMed ID: 9622980
[No Abstract] [Full Text] [Related]
10. Selection of glycoprotein IIb/IIIa inhibitors for upstream use in patients with diabetes experiencing unstable angina or non-ST segment elevation myocardial infarction. What have we learned in the last 10 years?
Silva MA; Gandhi PJ
J Clin Pharm Ther; 2004 Dec; 29(6):497-510. PubMed ID: 15584937
[TBL] [Abstract][Full Text] [Related]
11. Advancing the battle against acute ischemic syndromes: a focus on the GP IIb-IIIa inhibitors.
Dobesh PP; Latham KA
Pharmacotherapy; 1998; 18(4):663-85. PubMed ID: 9692642
[TBL] [Abstract][Full Text] [Related]
12. Intravenous glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: lessons from recently conducted randomized clinical trials.
Boersma E; Westerhout CM
Curr Opin Investig Drugs; 2004 Mar; 5(3):313-9. PubMed ID: 15083598
[TBL] [Abstract][Full Text] [Related]
13. Platelet glycoprotein IIb/IIIa inhibition as adjunctive therapy during primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction.
Young JJ
J Invasive Cardiol; 2005 Jun; 17(6):300-1. PubMed ID: 16003003
[No Abstract] [Full Text] [Related]
14. New antiplatelet agents for acute coronary syndromes.
Ferguson JJ; Lau TK
Am Heart J; 1998 May; 135(5 Pt 2 Su):S194-200. PubMed ID: 9588400
[No Abstract] [Full Text] [Related]
15. [Platelet glycoprotein IIB-IIIA receptor inhibitors in patients with ischemic heart disease].
Patti G; Fossati C; Manzoli A; D'Ambrosio A; Abbate A; Montesanti R; Di Sciascio G
Clin Ter; 2000; 151(4):301-6. PubMed ID: 11107681
[TBL] [Abstract][Full Text] [Related]
16. Increased reperfusion by glycoprotein IIb/IIIa receptor antagonist administration in case of unsuccessful and failed thrombolysis in patients with acute myocardial infarction: a pilot study.
Di Pasquale P; Sarullo FM; Cannizzaro S; Vitrano MG; Giubilato A; Scalzo S; Giambanco F; Paterna S
Ital Heart J; 2001 Oct; 2(10):751-6. PubMed ID: 11721719
[TBL] [Abstract][Full Text] [Related]
17. Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes.
Braunwald E; Maseri A; Armstrong PW; Califf RM; Gibler WB; Hamm CW; Simoons ML; Van de Werf F
Eur Heart J; 1998 Apr; 19 Suppl D():D22-30. PubMed ID: 9597519
[TBL] [Abstract][Full Text] [Related]
18. Platelet glycoprotein IIb/IIIa receptor blockers: An appropriate-use model for expediting care in acute coronary syndromes.
Kereiakes DJ; McDonald M; Broderick T; Roth EM; Whang DD; Martin LH; Howard WL; Schneider J; Shimshak T; Abbottsmith CW
Am Heart J; 2000 Feb; 139(2 Pt 2):S53-60. PubMed ID: 10650317
[No Abstract] [Full Text] [Related]
19. Glycoprotein IIb-IIIa antagonists in percutaneous coronary interventions and acute coronary syndromes.
Ramanathan A; Kleiman NS
Indian Heart J; 1998 Oct; 50 Suppl 1():45-56. PubMed ID: 9824907
[No Abstract] [Full Text] [Related]
20. Use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease.
Subbarao VD; Phillips J; Stouffer GA
Am J Med Sci; 1999 Aug; 318(2):107-14. PubMed ID: 10452570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
